Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
CERS logo CERS
Upturn stock ratingUpturn stock rating
CERS logo

Cerus Corporation (CERS)

Upturn stock ratingUpturn stock rating
$1.42
Last Close (24-hour delay)
Profit since last BUY-3.4%
upturn advisory
Consider higher Upturn Star rating
BUY since 14 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/27/2025: CERS (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

5 Analysts rated it

Moderately tracked stock, growing coverage, gaining market and investor attention.

1 Year Target Price $4.67

1 Year Target Price $4.67

Analysts Price Target For last 52 week
$4.67Target price
Low$1.12
Current$1.42
high$2.54

Analysis of Past Performance

Type Stock
Historic Profit -70.08%
Avg. Invested days 18
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/27/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 271.45M USD
Price to earnings Ratio -
1Y Target Price 4.67
Price to earnings Ratio -
1Y Target Price 4.67
Volume (30-day avg) 5
Beta 1.54
52 Weeks Range 1.12 - 2.54
Updated Date 06/30/2025
52 Weeks Range 1.12 - 2.54
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.1

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -10.23%
Operating Margin (TTM) -13.54%

Management Effectiveness

Return on Assets (TTM) -3.82%
Return on Equity (TTM) -35.69%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 288063276
Price to Sales(TTM) 1.47
Enterprise Value 288063276
Price to Sales(TTM) 1.47
Enterprise Value to Revenue 1.56
Enterprise Value to EBITDA -13.19
Shares Outstanding 191160000
Shares Floating 165506744
Shares Outstanding 191160000
Shares Floating 165506744
Percent Insiders 3.35
Percent Institutions 76.13

Analyst Ratings

Rating 3
Target Price 4.67
Buy -
Strong Buy 4
Buy -
Strong Buy 4
Hold 1
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Cerus Corporation

stock logo

Company Overview

overview logo History and Background

Cerus Corporation was founded in 1991. Initially focused on protein research, it transitioned to blood safety technology, achieving significant milestones with INTERCEPT Blood System approvals in Europe and the US.

business area logo Core Business Areas

  • Blood Safety: Develops and commercializes the INTERCEPT Blood System, a technology designed to inactivate pathogens in blood components (platelets, plasma, and red blood cells) used for transfusions. This reduces the risk of transfusion-transmitted infections.

leadership logo Leadership and Structure

Cerus is led by William 'Obi' Greenman (President and CEO). The organizational structure is functional, with departments for R&D, manufacturing, commercial operations, and finance.

Top Products and Market Share

overview logo Key Offerings

  • INTERCEPT Blood System: A pathogen reduction technology for blood components. It inactivates a broad range of viruses, bacteria, parasites, and leukocytes in platelets, plasma, and red blood cells. Competitors are companies using bacterial detection methods or other pathogen inactivation technologies. It is challenging to obtain precise market share data, but INTERCEPT has a significant presence in regions where pathogen reduction is mandated or highly recommended. Revenue is dependent on system adoption by blood banks and hospitals.

Market Dynamics

industry overview logo Industry Overview

The blood safety market is driven by the need to reduce transfusion-transmitted infections and improve patient safety. Regulatory mandates and hospital adoption are key drivers. The market is growing due to increasing awareness and emerging infectious diseases.

Positioning

Cerus is a leader in pathogen reduction technology for blood components. Its competitive advantage lies in its broad-spectrum pathogen inactivation capabilities and regulatory approvals.

Total Addressable Market (TAM)

The TAM is estimated to be in the billions of dollars, encompassing all blood components used in transfusions globally. Cerus's position is strong in markets with pathogen reduction mandates, but it aims to expand further into regions with less stringent regulations. Current market adoption is estimated to be less than 20% of the total potential transfusion market for pathogen reduction

Upturn SWOT Analysis

Strengths

  • FDA-approved technology
  • Broad-spectrum pathogen inactivation
  • Established presence in key markets
  • Growing regulatory support for pathogen reduction

Weaknesses

  • High cost of INTERCEPT system compared to alternatives
  • Dependence on regulatory mandates for market adoption
  • Limited product portfolio beyond blood safety
  • Variable adoption rates across different regions

Opportunities

  • Expansion into new geographic markets
  • Development of new applications for INTERCEPT technology
  • Partnerships with blood banks and hospitals
  • Increasing awareness of transfusion-transmitted risks

Threats

  • Competition from alternative blood safety technologies
  • Resistance from blood banks due to cost concerns
  • Changes in regulatory landscape
  • Emergence of new blood-borne pathogens

Competitors and Market Share

competitor logo Key Competitors

  • Baxalta (now Takeda) (TAK)
  • Grifols (GRFS)

Competitive Landscape

Cerus competes with companies offering alternative blood safety technologies. Its key advantage is its broad-spectrum pathogen inactivation. Disadvantages include high cost versus other blood screening technologies.

Growth Trajectory and Initiatives

Historical Growth: Cerus has experienced revenue growth driven by increased adoption of INTERCEPT in key markets.

Future Projections: Analysts project continued revenue growth as pathogen reduction becomes more widely adopted. Profitability is expected to improve over time.

Recent Initiatives: Cerus is focusing on expanding its market presence in the US and other regions. They are also working on new applications for the INTERCEPT technology.

Summary

Cerus Corporation is a key player in the blood safety market with its INTERCEPT technology. While it faces challenges related to cost and market adoption, its broad-spectrum pathogen inactivation capabilities provide a competitive advantage. The company is growing revenue but still operating at a loss. Continued expansion and strategic partnerships will be crucial for future success.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company SEC Filings (10-K, 10-Q), Analyst Reports, Industry Reports

Disclaimers:

This analysis is for informational purposes only and should not be considered investment advice. Market share data is based on estimates and may vary.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Cerus Corporation

Exchange NASDAQ
Headquaters Concord, CA, United States
IPO Launch date 1997-01-30
CEO -
Sector Healthcare
Industry Medical Devices
Full time employees 614
Full time employees 614

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma and cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California.